The company will try to get the Komzifti QTc prolongation warning removed.
ApexOnco Front Page
Recent articles
It’s less about being fast, more about producing a better product.
With a phase 3 trial of the trispecific T-cell engager ramantamig, J&J will challenge itself.
The company’s AN9025 will shortly enter phase 1.
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
Though lung cancer looks promising a partner is now needed.
But the group still hopes to get IGV-001 approved based on overall survival data.
A more comprehensive dataset on JANX007 sends the group’s stock down.
